An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

Detalles Bibliográficos
Autores principales: Fiedler, Walter, Montesinos, Pau, Schliemann, Christoph, Middeke, Jan, Vasu, Sumithira, Scholz, Christian W., Esteve, Jordi, Mondal, Shoubhik, Rüter, Björn, Burkard, Ute, Osswald, Annika, Blum, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713566/
https://www.ncbi.nlm.nih.gov/pubmed/36005556
http://dx.doi.org/10.3324/haematol.2022.281128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713566/
https://www.ncbi.nlm.nih.gov/pubmed/36005556
http://dx.doi.org/10.3324/haematol.2022.281128

Ejemplares similares